Drug Profile
Dipraglurant - Addex Therapeutics
Alternative Names: ADX-48621; Dipraglurant-ER; Dipraglurant-IR; mGluR5-NAMLatest Information Update: 17 Aug 2023
Price :
$50
*
At a glance
- Originator Addex Pharmaceuticals
- Developer Addex Therapeutics
- Class Alkynes; Antidepressants; Anxiolytics; Heterocyclic bicyclo compounds; Imidazoles; Muscle relaxants; Neuropsychotherapeutics; Pyridines; Small molecules
- Mechanism of Action Metabotropic glutamate receptor 5 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Drug-induced dyskinesia
- Phase II Blepharospasm; Torticollis
- Preclinical Neurological disorders
- No development reported Major depressive disorder
- Discontinued Anxiety disorders